Skip to main content
OpenTrials
Completed

NCT Number: NCT02701062

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who develop Post-operative Atrial Fibrillation (POAF) and receive the AtriClip will be followed for 365 days post index procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sharp Memorial Hospital, San Diego, California, United States

Loading trial locations.

About this study

Patients without a documented history of AF but who present with a CHA2DS2- VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category) of => 2 and HASBLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) of => 2 and will undergo a valve or CABG (structural heart) procedure with direct visual access to the LAA will be eligible to participate based upon the inclusion and exclusion criteria defined in this protocol. Up to 2000 patients will enroll at up to 40 sites and will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who not develop Post-operative Atrial Fibrillation (POAF) will be followed for 30 days for safety. Subjects who develop POAF and receive the AtriClip will be followed for 365 days post index procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:

  • Age > 18 years male or female.
  • Scheduled for any non-mechanical valve and/or CABG (structural heart) procedure where direct access to the LAA is expected.
  • No documented preoperative AF.
  • CHA2DS2-VASc score of => 2.
  • HASBLED score of => 2.
  • Acceptable surgical candidate, including use of general anesthesia.
  • Willing and able to provide written informed consent.

Exclusion criteria

Patients satisfying the following criteria will not be eligible for participation:

  • Redo cardiac surgery.
  • Mechanical heart valve or other anticipated or current requirement for anticoagulation therapy during the post-operative (30 day) period.
  • Hypercoagulability conditions that may confound the study.
  • Ejection Fraction < 30.
  • Left Atrium > 6 cm.
  • Severe Diastolic Dysfunction.
  • Requires anticoagulation therapy.
  • Patient had a stroke/cerebrovascular accident (CVA) within previous 30 days prior to signing informed consent.

Intra-Operative Exclusion Criteria

  • Presence of thrombus in the left atrium or LAA.
  • LAA tissue is deemed friable or has significant adhesions (as evaluated by the surgeon) near or on the LAA making AtriClip placement overly risky.
  • Left atrial appendage is outside the range of manufacturer's recommendations - width < 29mm or > 50mm.
  • Direct visualization access is not available for AtriClip placement.

Treatment and study plan

AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems

Device

Other names: AtriClip FLEX (ACH2), AtriClip Long (LAA), AtriClip Standard (ACH1)

Anticoagulation Therapy

Drug

Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.

Other names: Warfarin/Coumadin, New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban

Primary outcomes

  1. Number of Perioperative Complications Associated With AtriClip Placement

    Time frame: Within any 24 hour period during the first 2 days post-index procedure

    Defined as: stroke, major bleeding that requires re-operation and/or transfusion of > 2 U packed red blood cells (PRBC), myocardial infarction (MI), or death.

Secondary outcomes

  1. Number of Subjects With Intraoperative Successful Exclusion of LAA.

    Time frame: Intraoperative period

    Successful exclusion of LAA is defined as no (0 mm) flow between LAA and LA and < 5 mm LAA remnant by intraoperative TEE with Doppler.

  2. Composite Event Rates Between Subjects Diagnosed With Post-operative Atrial Fibrillation (POAF) (Through 365 Days)

    Time frame: 365 days post index procedure

    Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.

  3. Composite Event Rates Between Subjects Not Diagnosed With POAF (Through 30 Days)

    Time frame: 30 days Post-Procedure

    Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.

  4. Composite Event Rates for ALL Subjects Regardless of POAF Through 365 Days

    Time frame: 365 Days Post-Procedure

    Events to be evaluated include: Thromboembolic & Hemorrhagic Events such as cerebrovascular accident (CVA), transient ischemic attack (TIA), peripheral ischemia, hemorrhagic stroke, neurologic bleed, gastrointestinal (GI) bleeds, or other major bleeding event.

  5. Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Mean Values)

    Time frame: 365 Days Post-Procedure

    Healthcare resource utilization variance between groups as related to hospital length-of-stay (LOS) and hospital readmissions.

  6. Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Median Values)

    Time frame: 365 Days Post-Procedure

    Healthcare resource utilization variance between groups as related to hospital length-of-stay (LOS) and hospital readmissions.

  7. Healthcare Resource Utilization Variance Between Groups as Related to the Composite Events Above (Event Rates)

    Time frame: 365 Days Post-Procedure

    Specifically, reoperation for bleeding, neurologic consults for stroke or TIA, and emergency department (ED) visits.

Sponsors and collaborators

Lead sponsor

AtriCure, Inc.

Industry

Registry information

Acronym: ATLAS

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Mar 8, 2016
Registry last updated
Nov 24, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.